The Rotation of Disinfectants Principle: True or False? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Rotation of Disinfectants Principle: True or False?
The author defines sanitizers, disinfectants, and antibiotics, and examines the question of whether the rotation of disinfectants is scientifically warranted.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 58-71

75. P.G. Ambrose et al., "New Generations of Quinolones: with Particular Attention to Levofloxacin," Conn. Med. 61, 269–272 (1997).

76. L. Ferrero, B. Cameron, and J. Crouzet, "Analysis of gyrA and grlA Mutations in Stepwise-Selected Ciprofloxacin-Resistant Mutants of Staphylococcus aureus, " AAC. 39, 1554–1558 (1995).

77. P. Heisig, "Genetic Evidence for a Role of parC Mutations in Development of High Level Fluoroquinolone Resistance in Escherichia coli, " AAC. 40, 879–885 (1996).

78. C. Janoir et al., "High-Level Fluoroquinolone Resistance in Streptococcus pneumoniae Requires Mutations in parC and gyrA," AAC. 40, 2760–2764 (1996).

79. X.S. Pan and L.M. Fisher, "DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae, " AAC. 42, 2810–2816 (1998).

80. H. Taba and N. Kusano, "Sparfloxacin Resistance in Clinical Isolates of Streptococcus pneumoniae : Involvement of Multiple Mutations in gyrA and parC Genes", AAC. 42, 2193–2196 (1998).

81. X. Zhao et al., "DNA Topoisomerse Targets of the Fluoroquinolones: A Strategy for Avoiding Bacterial Resistance," Proc. Natl. Acad. Sci. U.S.A. 94, 13991–13996 (1997).

82. D.C. Hooper, "Mode of Action of Fluoroquinolones," Drugs 58 (suppl 2), 6–10 (1999).

83. C. Siporin, "The Evolution of Fluorinated Quinolones: Pharmacology, Microbiological Activity, Clinical Uses, and Toxicities," Annu. Rev. Microbiol. 43, 601–627 (1989).

84. H. Hiasa, D.O. Yousef, and K.J. Marains, "DNA Strand Cleavage Is Required for Replication Fork Arrest by a Frozen Topoisomerase-Quinolone-DNA Ternary Complex," J. Biol. Chem. 271, 26424–26429 (1996).

85. C.R. Chen et al., "DNA Gyrase and Topoisomerase IV on the Bacterial Chromosome: Quinolone-Induced DNA Cleavage," J. Mol. Biol. 258, 627–637 (1996).

86. R.A. Nicholas, H. Hamilton, and M.S. Cohen, "Beta-Lactam Antibiotics," in Principles of Pharmacology, P.L. Munson, R.A. Mueller, and G.R. Breese, Eds. (Chapman and Hall, NY, 1995), p. 95.

87. K. Poole, "Resistance to Beta-Lactam Antibiotics," Cell. Mol. Life Sci. 61 (17), 2200–2223 (2004).

88. "Antibiotics—Protein Synthesis, Nucleic Acid Synthesis, and Metabolism," in Microbiology and Immunology, University of South Carolina, http://pathmicro.med.sc.edu/fox/antibiotics1.htm accessed Jan. 18, 2009.

89. G.M. Brown, "The Biosynthesis of Folic Acid II: Inhibition by Sulfonamides," J. Biol. Chem. 237, 536–540 (1962).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here